Skip to content
ClinCalc Pro
Menu
Soluble Guanylate Cyclase Stimulator — PAH / CTEPH

Riociguat

Brand names: Adempas

Riociguat is an oral soluble guanylate cyclase stimulator used by specialists to treat pulmonary arterial hypertension and inoperable or persistent chronic thromboembolic pulmonary hypertension. It is initiated and titrated under a specialist pulmonary hypertension service.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It both sensitises soluble guanylate cyclase to endogenous nitric oxide and directly stimulates the enzyme, raising cyclic GMP to produce pulmonary vasodilation.

Prescribing in practice

  • Riociguat is contraindicated in pregnancy because it is teratogenic, so pregnancy must be excluded and effective contraception with monthly pregnancy testing maintained in those who can become pregnant.
  • It must not be combined with PDE5 inhibitors or nitrates because of the risk of severe hypotension.
  • Titrate against blood pressure and symptoms, and use caution in patients prone to hypotension.

Monitoring

Monitor blood pressure during titration, watch for symptomatic hypotension and haemoptysis, and conduct monthly pregnancy testing where applicable.

Counselling the patient

  • Do not use this with erectile-dysfunction medicines or any nitrate, and tell other prescribers you take it.
  • Effective contraception is essential and you will need regular pregnancy tests.
  • Report dizziness, fainting or coughing up blood.

Evidence & guidelines

NICE and trial evidence support riociguat for pulmonary arterial hypertension and inoperable or persistent chronic thromboembolic pulmonary hypertension.

Reference: CHEST-1 Trial (Ghofrani et al. NEJM 2013); PATENT-1 Trial (Ghofrani et al. NEJM 2013); ESC/ERS PAH Guidelines 2022; NICE TA401; SPC Adempas; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.